Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 21 Results

Title
Intervention Indication Therapeutic Area Year Actions
Sacituzumab govitecan for urothelial cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Urothelial cancer Urological Cancer 2022 View  |  Download
Pembrolizumab perioperative therapy with neoadjuvant chemotherapy for treating cisplatin eligible muscle-invasive bladder cancer Chemotherapy , Pembrolizumab (Keytruda; MK-3475) Bladder cancer Urological Cancer 2022 View  |  Download
Pembrolizumab in addition to chemotherapy for advanced or metastatic urothelial cancer - first line Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2018 View  |  Download
Oportuzumab monatox for non-muscle invasive bladder cancer - second line Oportuzumab monatox (Vicinium; VB4-845; Proxinium) Bladder cancer Urological Cancer 2020 View  |  Download
Nivolumab in combination with ipilimumab for previously untreated unresectable or metastatic urothelial cancer – first-line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Urothelial cancer Urological Cancer 2020 View  |  Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Bladder cancer Oncology , Urological Cancer 2021 View  |  Download
Nivolumab in combination with chemotherapy for previously untreated unresectable or metastatic urothelial cancer Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538) Urothelial cancer Urological Cancer 2022 View  |  Download
Nivolumab for high risk invasive urothelial carcinoma - adjuvant Nivolumab (Opdivo; BMS-936558; ONO-4538) Urothelial cancer Urological Cancer 2019 View  |  Download
Erdafitinib capsules for metastatic or surgically unresectable urothelial cancer with FGFR gene aberrations – second line therapy Erdafitinib (JNJ-42756493; BALVERSA) Urothelial cancer Urological Cancer 2017 View  |  Download
Enfortumab vedotin with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer Enfortumab vedotin (ASG-22ME; Padcev) , Pembrolizumab (Keytruda; MK-3475) Urothelial cancer Urological Cancer 2022 View  |  Download
1 2 3
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications